Topigen Pharmaceuticals Inc.

TOPIGEN is a privately-held biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. TOPIGEN,s pipeline includes small molecule and RNA-based therapeutics. The Company,s Phase II products and research programs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis. For more detailed information on TOPIGEN visit www.topigen.com. ( www.topigen.com )